Wen-Jye Lin

Dr. Wen-Jye Lin

National Health Research Institutes, Taiwan, ROC

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2013 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
KIKouji Izumi
Kouji Izumi
LFLei‐Ya Fang
Lei‐Ya Fang
AMAtsushi Mizokami
Atsushi Mizokami
MNMikio Namiki
Mikio Namiki
LLLei Li
Lei Li
CCChawnshang Chang
Chawnshang Chang
Increased CCL2 expression in prostate cancer (PCa) cells enhanced metastasis via macrophage recruitment. However, its linkage to androgen receptor (AR)‐mediated PCa progression remains unclear. Here, we identified a previously unrecognized regulation: targeting AR with siRNA in PCa cells increased macrophage recruitment via CCL2 up‐regulation, which might then result in enhancing PCa invasiveness. Molecular mechanism dissection revealed that targeting PCa AR with siRNA promoted PCa cell migration/invasion via CCL2‐dependent STAT3 activation and epithelial–mesenchymal transition (EMT) pathways. Importantly, pharmacologic interruption of the CCL2/CCR2‐STAT3 axis suppressed EMT and PCa cell migration, providing a new mechanism linking CCL2 and EMT. Simultaneously targeting PCa AR with siRNA and the CCL2/CCR2‐STAT3 axis resulted in better suppression of PCa growth and metastasis in a xenograft PCa mouse model. Human PCa tissue microarray analysis suggests that increased CCL2 expression may be potentially associated with poor prognosis of PCa patients. Together, these results may provide a novel therapeutic approach to better battle PCa progression and metastasis at the castration resistant stage via the combination of targeting AR with siRNA and anti‐CCL2/CCR2‐STAT3 signalling.

15 September 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LFLei-Ya Fang
Lei-Ya Fang
KIKouji Izumi
Kouji Izumi
KLKuo-Pao Lai
Kuo-Pao Lai
LLLiang Liang
Liang Liang
LLLei Li
Lei Li
CCChawnshang Chang
Chawnshang Chang
Infiltrating macrophages are a key component of inflammation during tumorigenesis, but the direct evidence of such linkage remains unclear. We report here that persistent coculturing of immortalized prostate epithelial cells with macrophages, without adding any carcinogens, induces prostate tumorigenesis and that induction involves the alteration of signaling of macrophage androgen receptor (AR)-inflammatory chemokine CCL4–STAT3 activation as well as epithelial-to-mesenchymal transition and downregulation of p53/PTEN tumor suppressors. In vivo studies further showed that PTEN+/− mice lacking macrophage AR developed far fewer prostatic intraepithelial neoplasia (PIN) lesions, supporting an in vivo role for macrophage AR during prostate tumorigenesis. CCL4-neutralizing antibody effectively blocked macrophage-induced prostate tumorigenic signaling and targeting AR via an AR-degradation enhancer, ASC-J9, reduced CCL4 expression, and xenografted tumor growth in vivo. Importantly, CCL4 upregulation was associated with increased Snail expression and downregulation of p53/PTEN in high-grade PIN and prostate cancer. Together, our results identify the AR-CCL4-STAT3 axis as key regulators during prostate tumor initiation and highlight the important roles of infiltrating macrophages and inflammatory cytokines for the prostate tumorigenesis. Cancer Res; 73(18); 5633–46. ©2013 AACR.

26 December 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
AMAerken Maolake
Aerken Maolake
KIKouji Izumi
Kouji Izumi
KSKazuyoshi Shigehara
Kazuyoshi Shigehara
ANAriunbold Natsagdorj
Ariunbold Natsagdorj
HIHiroaki Iwamoto
Hiroaki Iwamoto
AMAtsushi Mizokami
Atsushi Mizokami
Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22CCR4 axis

13 November 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
ANAriunbold Natsagdorj
Ariunbold Natsagdorj
KIKouji Izumi
Kouji Izumi
KHKaoru Hiratsuka
Kaoru Hiratsuka
KMKazuaki Machioka
Kazuaki Machioka
HIHiroaki Iwamoto
Hiroaki Iwamoto
AMAtsushi Mizokami
Atsushi Mizokami
Understanding the mechanism of chemoresistance and disease progression in patients with prostate cancer is important for developing novel treatment strategies. In particular, developing resistance to cabazitaxel is a major challenge in patients with docetaxel‐resistant and castration‐resistant prostate cancer (CRPC) because cabazitaxel is often administered as a last resort. However, the mechanism by which cabazitaxel resistance develops is still unclear. C‐C motif chemokine ligands (CCL) were shown to contribute to the castration resistance of prostate cancer cells via an autocrine mechanism. Therefore, we focused on CCL as key factors of chemoresistance in prostate cancer cells. We previously established a cabazitaxel‐resistant cell line, DU145‐TxR/CxR, from a previously established paclitaxel‐resistant cell line, DU145‐TxR. cDNA microarray analysis revealed that the expression of CCL2 was upregulated in both DU145‐TxR and DU145‐TxR/CxR cells compared with DU145 cells. The secreted CCL2 protein level in DU145‐TxR and DU145‐TxR/CxR cells was also higher than in parental DU145 cells. The stimulation of DU145 cells with CCL2 increased the proliferation rate under treatments with cabazitaxel, and a CCR2 (a specific receptor of CCL2) antagonist suppressed the proliferation of DU145‐TxR and DU145‐TxR/CxR cells under treatments of cabazitaxel. The CCL2‐CCR2 axis decreased apoptosis through the inhibition of caspase‐3 and poly(ADP‐ribose) polymerase (PARP). CCL2 is apparently a key contributor to cabazitaxel resistance in prostate cancer cells. Inhibition of the CCL2‐CCR2 axis may be a potential therapeutic strategy against chemoresistant CRPC in combination with cabazitaxel.

28 March 2018 in Nano Letters
Verified
Journal Article
Closed access
FLFang-Hsuean Liao
Fang-Hsuean Liao
TWTe-Haw Wu
Te-Haw Wu
YHYu-Ting Huang
Yu-Ting Huang
Wen-Jye LinWen-Jye Lin
Wen-Jye Lin
CSChun-Jen Su
Chun-Jen Su
SLShu-Yi Lin
Shu-Yi Lin

19 December 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
KIKouji Izumi
Kouji Izumi
AMAtsushi Mizokami
Atsushi Mizokami
HLHsiu-Ping Lin
Hsiu-Ping Lin
HHHui-Min Ho
Hui-Min Ho
HIHiroaki Iwamoto
Hiroaki Iwamoto
Wen-Jye LinWen-Jye Lin
Wen-Jye Lin
Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer